Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) – Recommendations and Statements for Girls and Women

Abstract

Aim The aim of this official guideline published by the German Society of Gynecology and Obstetrics (DGGG) and coordinated with the German Society of Urology (DGU) and the German Society of Reproductive Medicine (DGRM) is to provide consensus-based recommendations, obtained by evaluating the relevant literature, on counseling and fertility preservation for prepubertal girls and boys as well as patients of reproductive age. Statements and recommendations for girls and women are presented below. Statements or recommendations for boys and men are not the focus of this guideline.

Methods This S2k guideline was developed at the suggestion of the guideline commission of the DGGG, DGU and DGRM and represents the structured consensus of representative members from various professional associations (n = 40).

Recommendations The guideline provides recommendations on counseling and fertility preservation for women and girls which take account of the patientʼs personal circumstances, the planned oncologic therapy and the individual risk profile as well as the preferred approach for selected tumor entities.

Key words

fertility preservation - oncologic diseases - guideline

• References/Literatur

• 1 von Wolff M, Dian D. Fertilitätsprotektion bei Malignomen und gonadotoxischen Therapien. Dtsch Arztebl Int 2012; 109: 220-226
• 2 Schover LR, Rybicki LA, Martin BA. et al. Having children after cancer. A pilot survey of survivorsʼ attitudes and experiences. Cancer 1999; 86: 697-709
• 3 Baysal O, Bastings L, Beerendonk CC. et al. Decision-making in female fertility preservation is balancing the expected burden of fertility preservation treatment and the wish to conceive. Hum Reprod 2015; 30: 1625-1634
• 4 Lee SJ, Schover LR, Partridge AH. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931
• 5 Lambertini M, Del Mastro L, Pescio MC. et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016; 14: 1
• 6 Wallace WH, Thomson AB, Saran F. et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62: 738-744
• 7 Sudour H, Chastagner P, Claude L. et al. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int J Radiat Oncol Biol Phys 2010; 76: 867-873
• 8 Levi Setti PE, Porcu E, Patrizio P. et al. Human oocyte cryopreservation with slow freezing versus vitrification. Results from the National Italian Registry data, 2007–2011. Fertil Steril 2014; 102: 90-95.e2
• 9 Nagy ZP, Anderson RE, Feinberg EC. et al. The Human Oocyte Preservation Experience (HOPE) Registry: evaluation of cryopreservation techniques and oocyte source on outcomes. Reprod Biol Endocrinol 2017; 15: 10
• 10 Fasano G, Fontenelle N, Vannin AS. et al. A randomized controlled trial comparing two vitrification methods versus slow-freezing for cryopreservation of human cleavage stage embryos. J Assist Reprod Genet 2014; 31: 241-247
• 11 Li Z, Wang YA, Ledger W. et al. Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing: a population-based cohort study. Hum Reprod 2014; 29: 2794-2801
• 12 Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril 2014; 101: 1237-1243
• 13 Meirow D, Roness H, Kristensen SG. et al. Optimizing outcomes from ovarian tissue cryopreservation and transplantation; activation versus preservation. Hum Reprod 2015; 30: 2453-2456
• 14 Dolmans MM, Luyckx V, Donnez J. et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 2013; 99: 1514-1522
• 15 Bastings L, Beerendonk CC, Westphal JR. et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 2013; 19: 483-506
• 16 Sukumvanich P, Case LD, Van Zee K. et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010; 116: 3102-3111
• 17 Hulvat MC, Jeruss JS. Fertility preservation options for young women with breast cancer. Curr Opin Obstet Gynecol 2011; 23: 174-182
• 18 Lawrenz B, Henes M, Neunhoeffer E. et al. Fertility conservation in breast cancer patients. Womens Health (Lond) 2011; 7: 203-212
• 19 Turan V, Bedoschi G, Moy F. et al. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013; 100: 1681-1685.e1
• 20 Sigismondi C, Papaleo E, Vigano P. et al. Fertility preservation in female cancer patients: a single center experience. Chin J Cancer 2015; 34: 56-60
• 21 Takae S, Sugishita Y, Yoshioka N. et al. The role of menstrual cycle phase and AMH levels in breast cancer patients whose ovarian tissue was cryopreserved for oncofertility treatment. J Assist Reprod Genet 2015; 32: 305-312
• 22 Dahhan T, Mol F, Kenter GG. et al. Fertility preservation: a challenge for IVF-clinics. Eur J Obstet Gynecol Reprod Biol 2015; 194: 78-84
• 23 Oktay K, Turan V, Bedoschi G. et al. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol 2015; 33: 2424-2429
• 24 Oktay K, Kim JY, Barad D. et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28: 240-244
• 25 Oktay K, Moy F, Titus S. et al. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol 2014; 32: 1093-1094
• 26 Shen YW, Zhang XM, Lv M. et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. OncoTargets Ther 2015; 8: 3349-3359
• 27 Lambertini M, Ceppi M, Poggio F. et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 2015; 26: 2408-2419